Versión de HTML Básico
43
Manuel Lobo González
Células madre en terapia celular cardíaca
42. Planat-Benard V, Silvestre JS, Cousin B, André M, Nibbelink M,
Tamarat R, et al. Plasticity of human adipose lineage cells toward en-
dothelial cells: physiological and therapeu- tic perspectives. Circulation.
2004 10;109:656-663.
43. Nieto-Aguilar R, Serrato D, Garzón I, Campos A, Alaminos M.
Pluripotential differentiation capability of human adipose-derived stem
cells in a novel fibrin-agarose scaffold.J Biomater Appl. 2011;25:743-68.
44. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP,
et al. “A randomized, double-blind, placebo-controlled, dose-escalation
study of intravenous adult human mesenchymal stem cells (prochymal)
after acute myocardial infarction,” Journal of the American College of Car-
diology, 2009:. 24,2277–2286.
45. Cai L, Johnstone BH, Cook TG, Tan J, Fishbein MC, et al. IFATS
collection: Human adipose tissue-derived stem cells induce angiogenesis
and nerve sprouting following myocardial infarction, in conjunction with
potent preservation of cardiac function. Stem Cells 2009;27: 230–7.
46. Valina C, Pinkernell K, Song YH, Bai X, Sadat S, Campeau RJ, et al.
Intracoronary administration of autologous adipose tissue-derived stem
cells improves left ventricular function, perfusion, and remodelling after
acute myocardial infarction. Eur Heart J 2007;28:2667–77.
47. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zam-
brano JP, et al .Comparison of allogeneic vs autologous bone marrow–de-
rived mesenchymal stem cells delivered by transendocardial injection in
patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
JAMA. 2012 12; 308:2369-79.
48. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho
D, Suncion V, et al .Enhanced effect of combining human cardiac stem
cells and bone marrow mesenchymal stem cells to reduce infarct size and
to restore cardiac function after myocardial infarction.Circulation. 2013
15;127:213-23.
49. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyo-
cardial bone marrow stem cell therapy of the heart: from the methodo-
logical origin to clinical practice. J Am Coll Cardiol. 2011 6;58:1095-104.
50. Vassalli G, Vanderheyden M, Renders F, Eeckhout E, Bartunek
J. Bone marrow stem cell therapy for cardiac repair: challenges and pers-
pectives. Minerva Cardioangiol. 2007;55:659-67.
51. Mills JS, Rao SV. REPAIR-AMI: stem cells for acute myocardial
infarction.Future Cardiol. 2007;3:137-40.
52. Erbs S, Linke A, Schächinger V, Assmus B, Thiele H, Diederich KW,
et al. Restoration of microvascular function in the infarct-related artery by
intracoronary transplantation of bone marrow progenitor cells in patients
with acute myocardial infarction: the Doppler Substudy of the Reinfusion
of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial
Infarction (REPAIR-AMI) trial. Circulation. 2007 24;116:366-74.
53. Dill T, Schächinger V, Rolf A, Möllmann S, Thiele H, Tillmanns
H, et al. Intracoronary administration of bone marrow-derived progenitor
cells improves left ventricular function in patients at risk for adverse re-
modeling after acute ST-segment elevation myocardial infarction: results
of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in
Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic reso-
nance imaging substudy. Am Heart J. 2009;157:541-7.
54. Schächinger V, Assmus B, Erbs S, Elsässer A, Haberbosch W,
Hambrecht R, et al. Intracoronary infusion of bone marrow-derived mo-
nonuclear cells abrogates adverse left ventricular remodelling post-acute
myocardial infarction: insights from the reinfusion of enriched progenitor
cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI)
trial.Eur J Heart Fail. 2009;11:973-9.
55. Assmus B, Rolf A, Erbs S, Elsässer A, Haberbosch W, Hambre-
cht R, et al. Clinical outcome 2 years after intracoronary administration of
bone marrow-derived progenitor cells in acute myocardial infarction.Circ
Heart Fail. 2010 ;3:89-96
56. Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schächin-
ger V, Lehmann R, et al.Transplantation of progenitor cells and regene-
ration enhancement in acute myocardial infarction (TOPCARE-AMI): fi-
nal 5-year results suggest long-term safety and efficacy. Clin Res Cardiol
2011;100:925–34.
57. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis
SG, et al; for the Cardiovascular Cell Therapy Research Network (CCTRN).
Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery
on Left Ventricular Function After Acute Myocardial Infarction: The TIME
Randomized Trial. JAMA. 2012 6:1-10.
58. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis
SG, et al; Cardiovascular Cell Therapy Research Network. Effect of the use
and timing of bone marrow mononuclear cell delivery on left ventricu-
lar function after acute myocardial infarction: the TIME randomized trial.
JAMA. 2012 12;308:2380-9.
59. Zhang C, Sun A, Zhang S, Yao K, Wu C, Fu M, et al. Efficacy and
safety of intracoronary autologous bone marrow-derived cell transplan-
tation in patients with acute myocardial infarction: insights from rando-
mized controlled trials with 12 or more months follow-up. Clin Cardiol.
2010 33:353-60.
60. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S,
et al. Stem cell treatment for acute myocardial infarction. Cochrane Data-
base Syst Rev 2012; 2: CD006536.
61. Smith AG. Embryo-derived stem cells: of mice and men.Annu
Rev Cell Dev Biol . 2001;17:435- 462.
62.Evans MJ, Kaufman MH. Establishment in culture of pluripoten-
tial cells from mouse embryos. Nature . 1981;292:154-156.
63. Martin GR. Isolation of a pluripotent cell line from early mouse
embry-os cultured in medium conditioned by teratocarcinoma stem cells.
Proc Natl Acad Ucid USA. 1981;78:7634-7638.
64. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel
JJ, Marshall VS, et al. Embryonic stem cell lines derived from humanblas-
tocysts. Science. 1998;282:1145–1147.
65. Huber I, Itzhaki I, Caspi O, Arbel G, Tzukerman M, Gepstein A, et
al. Identication and selection of cardiomyocytes during humanembryonic
stem cell differentiation. FASEB J.2007;21:2551-2563.
66. Solter D. From teratocarcinomas to embryonic stem cells
and beyond: a history of embryonic stem cell research.Nat Rev Genet .
2006;7:319-327.
67. Tomescot A, Leschik J, Bellamy V, Dubois G, Messas E, Bruneval
P, et al. Differentiation in vivo of cardiac committed human embryonic
stem cells in postmyocardial infarcted rats. Stem Cells. 2007;25:2200-
2205.
68. Behfar A, Faustino RS, Arrell DK, Dzeja PP, Perez-Terzic C, Terzic
A. Guided stem cell cardiopoiesis: discovery and translation. J Moll Cell
Cardiol 2008;45:523-529.
69. Faustino RS, Behfar A, Perez-Terzic C, Terzic A. Genomic chart
guiding embryonic stem cell cardiopoiesis. Genome Biol. 2008;9:R6 .
70. Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM,
Yamada S, et al. Cardiopoietic programming of embryonic stem cells for
tumor-free heart repair.J Exp Med. 2007 19;204:405-20.
71. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic
stem cells develop into multiple types of cardiac myocytes: action poten-
tial Heart disease and strokes update. Circ Res. 2003;93(1):32-9
72. Sartiani L, Bettiol E, Stillitano F, Mugelli A, Cerbai E, Jaconi ME.
Developmental changes in cardiomyocytes differentiated from human
embryonic stem cells: a molecular and electrophysiological approach.
Stem Cells. 2007;25:1136 –1144.
73. Hodgson DM, Behfar A, Zingman LV, Kane GC, Perez-Terzic C,
Alekseev AE, et al. Stable benefit of embryonic stem cell therapy in myo-
cardial infarction Am J Physiol Heart Physiol. 2004;287:H471-H479.
74. Ménard C, Hagège AA, Agbulut O, Barro M, Morichetti MC,
Brasselet C, et al .Transplantation of cardiaccommitted mouse embryonic
stem cells to infarcted sheep myocardium: a pre- clinical study. Lancet.
2005;366:1005-1012.
75. Yamada S, Nelson TJ, Crespo-Diaz RJ, Perez-Terzic C, Liu XK, Miki
T, et al. Embryonic stem cell therapy of heart failure in genetic cardiomyo-
pathy.Stem Cell 2008;26:2644-2653.
76. Murry CE, Keller G. Differentiation of embryonic stem cells to cli-